UGT1A1*28 genotype predicts gastrointestinal toxicity in patients treated with intermediate-dose Irinotecan

Pharmacogenomics

Volumn 10, Issue 5, 2009, Pages 733-739

  Ferraldeschi, Roberta ^a,b,c   Minchell, Laura J ^a,c   Roberts, Stephen A ^c   Tobi, Simon ^a,c   Hadfield, Kristen D ^a,c   Blackhall, Fiona H ^b   Mullamitha, Saifee ^b   Wilson, Gregory ^b   Valle, Juan ^b   Saunders, Mark ^b   Newman, William G ^a,c  

^a ST MARY S HOSPITAL   (United Kingdom)

^b CHRISTIE HOSPITAL   (United Kingdom)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Diarrhea; Irinotecan; Neutropenia; Pharmacogenetics; Toxicity; UGT1A1

Indexed keywords

CAPECITABINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; LOPERAMIDE; OXALIPLATIN; UFT; VASCULOTROPIN INHIBITOR; ANTINEOPLASTIC AGENT; BILIRUBIN URIDINE DIPHOSPHOGLUCURONOSYL TRANSFERASE 1A1; BILIRUBIN URIDINE-DIPHOSPHOGLUCURONOSYL TRANSFERASE 1A1; CAMPTOTHECIN; DNA; DRUG DERIVATIVE; GLUCURONOSYLTRANSFERASE;

ADULT; AGE; AGED; ARTICLE; CANCER STAGING; COLORECTAL CANCER; CONTROLLED STUDY; DIARRHEA; DRUG MEGADOSE; FEMALE; GASTROINTESTINAL TOXICITY; GENE; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE; HOMOZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PREDICTION; UGT1A1 GENE; UNITED KINGDOM; UNSPECIFIED SIDE EFFECT; CHEMICALLY INDUCED DISORDER; COHORT ANALYSIS; COLORECTAL TUMOR; DRUG EFFECT; ETHNIC GROUP; GASTROINTESTINAL TRACT; GENETIC VARIABILITY; GENETICS; ISOLATION AND PURIFICATION; MIDDLE AGED; PATHOLOGY; PREDICTION AND FORECASTING; PROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; COHORT STUDIES; COLORECTAL NEOPLASMS; DIARRHEA; DNA; DNA, NEOPLASM; ETHNIC GROUPS; FEMALE; GASTROINTESTINAL TRACT; GENETIC VARIATION; GENOTYPE; GLUCURONOSYLTRANSFERASE; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; YOUNG ADULT;

EID: 66849095621     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.09.20     Document Type: Article

References (23)

1. National Institute for Health and Clinical Excellence: Irinotecan, oxaliplatin and ralitrexad for the treatment of advanced colorectal cancer. Review of Technology Appraisal 33, 1-159 (2005).
2. Innocenti F, Ratain MJ: Pharmacogenetics of irinotecan: clinical perspectives on the utility of genotyping. Pharmacogenomics 7, 1211-1221 (2006).
3. Grothey AD, Sargent R, Goldberg M, Schmoll HJ: Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J. Clin. Oncol. 22, 1209-1214 (2004).
4. Rivory LP, Robert J: Identification and kinetics of a β-glucuronide metabolite of SN-38 in human plasma after administration of the camptothecin derivative irinotecan. Cancer Chemother. Pharmacol. 36, 176-179 (1995).
5. Kawato Y, Aonuma M, Hirota Y, Kuga H, Sato K: Intracellular roles of SN-38, a metabolite of the camptothecin derivative CpT-11, in the antitumor effect of CPT-11. Cancer Res. 51, 4187-4191 (1991).
6. Bosma PJ, Chowdhury JR, Bakker C et al.: The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. N. Engl. J. Med. 333, 1171-1175 (1995).
7. Ando Y, Saka H, Ando M et al.: Polymorphisms of UDP-91-Curonosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res. 60, 6921-6926 (2000).
8. Innocenti F, Undevia SD, Iyer L et al.: Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J. Clin. Oncol. 22, 1382-1388 (2004).
9. Rouits E, Boisdron-Cette M, Dumont A et al.: Relevance of different UGT1A1 polymorpbisms in irinotecan-induced toxicity: a molecular and clinical study of 75 patients. Clin. Cancer Res. 10, 5151-5159 (2004),
10. Marcuello E, Altes A, Menoyo A et al.: UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer. Br. J. Cancer 91, 678-682 (2004).
11. Carlini LE, Meropol NJ, Bever J et al.: UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotccan. Clin. Cancer Res. 11, 1226-1236 (2005).
12. Core JF, Kirzin S, Kramar A et al.: UGT1A1 polymorphism can predict haematologic toxicity in patients treated with irinotecan. Clin. Cancer Res. 13, 3269-3275 (2007).
13. Font A, Sanchez M, Taron E et al.: Weekly regimen of irinotecan/ docetaxel in previously treated non-small cell lung cancer patients and correlation with uridine diphosphate glucuronosyltransferase 1A1 ( UGT1A1) polymorphism. Invest. New Drugs 21, 435-443 (2003).
14. Massacesi CS, Terrazzino F, Marcucci MB et al.: Uridine diphosphate glucuronosyl transferase 1A1 promoter polymorphism predicts the risk of gastrointestinal toxicity and fatigue induced by irinotecan-based chemotherapy. Cancer 106, 1007-1016 (2006).
15. Toffoli GE, Cecchin G, Corona A et al.: The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer. J. Clin. Oncol. 24, 3061-3068 (2006).
16. Kweekel D, Guchelaar HJ, Gelderblom H: Clinical and phasmacogenetic factors associated with irinotecan toxicity. Cancer Treat. Rev. 34, 656-669 (2008).
17. Liu JY, Qu K, Sferruzza AD, Bender RA: Distribution of the UGT1A1*28 polymorphism in Caucasian and Asian populations in the US: a genomic analysis of 138 healthy individuals. Anticancer Drugs 18, 693-696 (2007).
18. Hoskins JM, Goldberg RM, Qu P, Ibrahim JG, McLeod HL: UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters. J. Natl. Cancer Inst. 99, 1290-1295 (2007).
19. Seymour MT, Maughan TS, Ledermann JA et al.: Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet 370, 143-152 (2007).
20. Kweekel DM, Gelderblom H, van der Straaten T, Antonioni NF, Punt CJA, Guchelaar H-J: UGT1A1*28 genotype and irinotecan dosage in patients with metastatic colorectal cancer: a Dutch Colorectal Cancer Group Study. Br. J. Cancer 99, 275-282 (2008).
21. Liu CY, Chen PM, Chiou TJ et al.: UGT1A1*28 polymorphism predicts irinotecan-induced severe toxicities without affecting treatment outcome and survival in patients with metastatic colorectal carcinoma. Cancer 112, 1932-1940 (2008).
22. Ruzzo A, Graziano F, Loupakis F et al.: Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first line FOLFIRI chemotherapy. Pharmacogenetics J. 8, 278-288 (2008).
23. Rouits E, Charasson V, Pétain A et al.: Pharmacokinctic and pharmacogenetic determinants of the activity and toxicity of irinotecan in metastatic colorectal cancer patients. Br. J. Cancer 99, 1239-1245 (2008).